One of the daunting aspects of Alzheimer's disease is that it is seldom diagnosed until victims have already lost significant cognitive function. Even if treatments are developed, they will not have sweeping impact unless -early-detection methods are devised.
One step toward this grail may come from psychiatrist and brain researcher Eric Reiman of the Banner Alzheimer's Institute in Phoenix. He has been using positron-emission tomography (PET) to study cognitively healthy people at three levels of genetic risk for the disease--those with two copies, one copy or no copies of the apolipoprotein E type 4 (APOE4) gene, which has been implicated in autopsies of Alzheimer's victims. Reiman says that APOE4 carriers show reduced metabolism in brain regions known to be affected by Alzheimer's disease and that "these reductions become more pronounced over time." He and his colleagues plan to use PET to evaluate high-risk groups as various therapies are undertaken, to try to reveal if a therapy shows any effect. "Our goal is to find an effective way to prevent [Alzheimer's] without having to lose a generation along the way," Reiman says.
This article was originally published with the title Seeing Alzheimer's Early.